E. David Crawford, MD, presented “Next Generation Imaging in Prostate Cancer – PYLARIFY​” during the 31st International Prostate Cancer Update in July 2021 in Snowbird, Utah.

How to cite: Crawford, E. David. Next Generation Imaging in Prostate Cancer – PYLARIFY.” July 2021. Accessed Jan 2022. https://grandroundsinurology.com/next-generation-imaging-in-prostate-cancer-pylarify/

Next Generation Imaging in Prostate Cancer – PYLARIFY

E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology and Professor of Urology at the University of California, San Diego, explains how next generation imaging (NGI) can benefit prostate cancer patients and improve care, focusing on PYLARIFY PET/CT. He begins by providing some background, defining biochemical failure, noting that conventional imaging has poor sensitivity, and briefly reviewing RADAR I and III guidelines. Dr. Crawford then gives an in-depth summary of the design, patient entry criteria, and results of the CONDOR study on the clinical utility of PYLARIFY PET/CT in patients with biochemical recurrence of prostate cancer and non-informative standard of care baseline imaging. He explains that CONDOR’s primary endpoint was correct localization rate (CLR) of PYLARIFY PET/CT imaging, meaning the percentage of patients with a 1-to-1 correspondence between lesion level localization of ≥1 lesion on PYLARIFY PET/CT imaging and the composite truth standard, and notes that the results far exceeded the 20% baseline for success, with PYLARIFY imaging detecting ≥1 lesion in 59-66% of patients. Dr. Crawford also looks at the secondary endpoint of percentage of patients with a change in intended treatment management due to PYLARIFY PET/CT, observing that 64% of evaluable patients saw a change in management.

About The 31st Annual International Prostate Cancer Update:

The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. Dr. Crawford delivered this educational activity during the 31st iteration of the meeting in July 2021 in Snowbird, Utah.